US 10696723
Activatable interleukin 12 polypeptides
granted A61KA61K2039/585A61K38/00
Quick answer
US patent 10696723 (Activatable interleukin 12 polypeptides) held by Werewolf Therapeutics, Inc. expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Werewolf Therapeutics, Inc.
- Grant date
- Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K2039/585, A61K38/00